Fig. 2From: Influence of vitreomacular interface score on treatment outcomes of anti-VEGF therapy for neovascular age-related macular degenerationsource optical coherence tomography (SS-OCT) B-scan images (A–E) and corresponding infrared images (F–J) of a left eye in a 78-year-old male patient with neovascular age-related macular degeneration, recorded before intravitreal injection of aflibercept. Yellow lines show 1.5 mm intervals centered on the fovea. A A horizontal SS-OCT B-scan image 3 mm above the fovea. The vitreomacular interface score was 4 by summing 1, 1, 1, 1, and 0 from the left. B A horizontal SS-OCT B-scan image 1.5 mm above the fovea. The vitreomacular interface score was 5 by summing 1, 1, 1, 1, and 1 from the left. C A horizontal SS-OCT B-scan image through the fovea. The vitreomacular interface score was 4 by summing 1, 1, 0, 1, and 1 from the left. D A horizontal SS-OCT B-scan image 1.5 mm beneath the fovea. The vitreomacular interface score was 3 by summing 0, 1, 0, 1, and 1 from the left. E A horizontal SS-OCT B-scan image 3 mm beneath the fovea. The vitreomacular interface score was 4 by summing 1, 1, 1, 1, and 0 from the left. In total, the 25-point vitreomacular interface score of this eye was 20. The 9-point score was 7, and the 1-point macular score was 0Representative images used to analyze the 25-point vitreomacular interface score. Horizontal swept-Back to article page